在低中等收入国家引入SGLT-2抑制剂与GLP-1受体激动剂后胰岛素用量及糖尿病并发症的降低:一项微观模拟研究
该微观模拟模型基于全球健康与人口获取心血管代谢疾病照护项目(HPACC)的79国调查数据与临床试验数据,估算在低中等收入国家使用胰岛素治疗的2型糖尿病患者加用GLP-1受体激动剂或SGLT-2抑制剂的效应。结果显示加用后胰岛素用量分别减少8.2 IU/天(IQR: 6.9, 9.5)与5.3 IU/天(IQR: 4.5, 6.2),每1000人年因糖尿病并发症损失的伤残调整生命年(DALYs)中位数从2.20(IQR: 1.49, 4.02)降至1.01(IQR: 0.61, 1.86)与1.25(IQR: 0.81, 2.29)。作者认为扩大这些新型降糖药在低中等收入国家的可及性可能带来显著公共卫生获益。
要点
- 在低中等收入国家,胰岛素治疗的2型糖尿病患者加用GLP-1受体激动剂或SGLT-2抑制剂可减少胰岛素用量。
- 加用GLP-1受体激动剂后每1000人年DALYs中位数从2.20降至1.01,加用SGLT-2抑制剂后降至1.25。
- 主要获益来自体重下降、心肾疾病减少与死亡率降低,严重低血糖预防带来的DALY获益较小。
核心结论
- 在低中等收入国家使用GLP-1受体激动剂或SGLT-2抑制剂管理2型糖尿病可能显著减少胰岛素用量及相关健康风险,改善结局并减少残疾。
- 作者认为扩大这些新型降糖药在低中等收入国家的可及性可能带来显著公共卫生获益。
研究设计与样本
- 微观模拟模型,使用全球健康与人口获取心血管代谢疾病照护项目(HPACC)数据集,涵盖79个国家的调查数据,并结合临床试验数据估算胰岛素剂量减少。
- 模型纳入基于体重的胰岛素给药公式,以及严重低血糖、心血管与肾脏结局、新疗法副作用和死亡的风险比。
- 主要结局为胰岛素剂量变化,次要结局为每1000人年因糖尿病并发症(微血管与大血管)损失的伤残调整生命年(DALYs)。
主要发现
- 加用GLP-1受体激动剂可使胰岛素剂量减少8.2 IU/天(IQR: 6.9, 9.5),加用SGLT-2抑制剂减少5.3 IU/天(IQR: 4.5, 6.2)。
- 每1000人年损失的DALYs中位数从2.20(IQR: 1.49, 4.02)降至加用GLP-1受体激动剂的1.01(IQR: 0.61, 1.86)和加用SGLT-2抑制剂的1.25(IQR: 0.81, 2.29)。
- 主要获益来自体重下降、心肾疾病减少和死亡率降低,严重低血糖预防带来的DALY获益较小。
临床怎么用
- 原文未据此给出推荐。
局限性
- 部分数据集无法区分1型与2型糖尿病。
- 依赖主要在高收入国家开展的临床试验的假设。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetes mellitus, particularly type 2 diabetes, is a growing health concern in low- and middle-income countries (LMICs). The potential impact of newer diabetes medications, such as glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT-2) inhibitors, on insulin dosage and health outcomes in these settings is not well understood. METHODS AND FINDINGS: We developed a microsimulation model to estimate the impact of treating patients with type 2 diabetes who use insulin with GLP-1 receptor agonists or SGLT-2 inhibitors in LMICs. The model utilized data from the Global Health and Population Project on Access to Care for Cardiometabolic Diseases (HPACC) dataset, encompassing surveys from 79 countries and clinical trial data to estimate insulin dose reduction. We incorporated weight-based insulin dosing formulas and hazard ratios for severe hypoglycemia, cardiovascular and renal outcomes, side effects of new therapies, and mortality. The primary outcome was the change in insulin dosage, and secondary outcomes were disability-adjusted life years (DALYs) lost per 1,000 person-years by diabetes complication (micro- and macro-vascular). Our results indicate that the addition of GLP-1 receptor agonists or SGLT-2 inhibitors could reduce insulin dosage by 8.2 IU/day (IQR: 6.9, 9.5) and 5.3 IU/day (IQR: 4.5, 6.2), respectively. The median DALYs lost per 1,000 person-years decreased from 2.20 (IQR: 1.49, 4.02) to 1.01 (IQR: 0.61, 1.86) with GLP-1 receptor agonists and 1.25 (IQR: 0.81, 2.29) with SGLT-2 inhibitors. Primary benefits arose from weight loss, decreased cardiorenal disease, and decreased mortality, with smaller DALY benefits from the prevention of severe hypoglycemia. Key limitations include the inability to differentiate between type 1 and type 2 diabetes in some datasets and reliance on assumptions from clinical trials conducted primarily in high-income countries. CONCLUSIONS: The introduction of GLP-1 receptor agonists and SGLT-2 inhibitors for managing type 2 diabetes in LMICs could significantly reduce insulin dosage and associated health risks, leading to improved outcomes and reduced disability. These findings suggest that expanding access to these newer diabetes medications in LMICs could have substantial public health benefits.
引用
- Reduced insulin use and diabetes complications upon introduction of SGLT-2 inhibitors and GLP1-receptor agonists in low- and middle-income countries: A microsimulation. PLoS Med. 2025. PMID: 40245017. doi:10.1371/journal.pmed.1004559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。